Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14464189 | 0.84 | ALDH1A1 (0.79) | ALDH1A1KMT2ALMNAGAAPOLB | |
| SCHEMBL1804893 | 0.80 | ALDH1A1 (0.66) | ALDH1A1KMT2ALMNAGAAPOLB | |
| SCHEMBL20004086 | 0.80 | POLB (0.59) | LMNAPOLBKDM4EBCHEACHE | |
| SCHEMBL1127229 | 0.79 | KMT2A (0.66) | ALDH1A1KMT2ALMNAGAAPOLB | |
| SCHEMBL22495425 | 0.79 | KMT2A (0.74) | ALDH1A1KMT2ALMNAGAAPOLB | |
| SCHEMBL3654709 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KMT2ALMNAGAAPOLB | |
| SCHEMBL6427075 | 0.78 | GAA (0.65) | ALDH1A1KMT2ALMNAGAAPOLB | |
| SCHEMBL4921368 | 0.78 | ALDH1A1 (0.75) | ALDH1A1KMT2ALMNAGAAPOLB | |
| SCHEMBL7814507 | 0.78 | ALDH1A1 (0.66) | ALDH1A1KMT2ALMNAGAAPOLB | |
| SCHEMBL22495455 | 0.78 | SLC6A9 (0.53) | ALDH1A1KMT2ALMNAGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2626361-A1 | Pyrrole antifungal agents | F2G Limited (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | disclosed |
| EP-0918770-A1 | PYRIDYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | AstraZeneca AB (SE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998001447-A1 | PYRIDYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ZENECA LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | ALDH1A1 614/4885KMT2A 3378/4885LMNA 1934/4885 |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | ALDH1A1 219/4885KMT2A 3996/4885LMNA 3641/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | ALDH1A1 219/4885KMT2A 3996/4885LMNA 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.